Curasight has reported its Q2/21 quarterly report. The financial P&L is not of great importance for an upcoming biotech company, but it is encouraging to see great cost discipline. The company has made great progress at lower costs than expected and is now, on the back of encouraging preclinical and clinical data, ready to accelerate its plans for uTREAT (therapy) and uTRACE (diagnostic) further. During the quarter Kirsten Drejer (former Symphogen) was elected to the board.

Länk till analysen